New meta-analysis further supports low re-excisions and high placement accuracy with the Magseed® marker
An independent meta-analysis from January 2026, pooling 2,117 patients and 2,176 Magseed® marker placements, has reported low re-excision rates (8.2%) and low positive margins (7.6%) when the marker is used to localise non-palpable breast lesions prior to breast‑conserving surgery (BCS).
Al Darwashi et al. (2026) pooled 16 studies to evaluate safety and efficacy outcomes when the Magseed® marker was used for preoperative localisation of non-palpable lesions prior to BCS. The authors reported high placement accuracy, reliable intraoperative retrieval and low rates of positive margins, re-excisions and complications.
In a cohort cited by the review, Moreno‑Palacios et al. (2024) also observed that Magseed® marker facilitates less extensive resections compared to guidewires, promising improved cosmetic outcomes while maintaining oncological efficacy.
The key findings
- Low re-operation burden: Positive margins occurred in just 7.6% of cases, and only 8.2% required re-excision across the included series.
- High placement accuracy: The success rate for Magseed® marker placement showed 99.3% positioned within 10 mm of the lesion. Of note, 96.6% of Magseed® markers were placed within an even stricter 5 mm radius.
- Reliable retrieval: The pooled intraoperative retrieval success was 99.6% for the Magseed® marker.
"This meta-analysis demonstrated Magseed as a safe and effective preoperative localisation technique for BCS in the management of selected non-palpable breast lesions."Al Darwashi et al. (2026)
Ready to find out more about the Magseed® marker and the Sentimag® system?
→ Speak to a Magseed® marker expert
→ Read the full paper here
Magseed® is a trademark of Hologic, Inc. or its subsidiaries in the United States or other countries. Intended for medical professionals and use in the U.S., UK and the EU only.